Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
Thursday, July 30, 2020 1:05:39 PM
The company initiated a phase III earlier this week. The phase III study is evaluating 100 micrograms dose of mRNA-1273 administered on a two-dose vaccination schedule, given 28 days apart for safety and reactogenicity.
Moderna has also completed enrollment in a phase II study on mRNA-1273, which the company is conducting under its own investigational new drug application in June. The study is evaluating 50 µg and 100 µg doses of mRNA-1273. Interim data from a phase I study, announced earlier this month, demonstrated that participants vaccinated twice with mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2.
Scroll to continue with contentAd
The company has been developing other mRNA-based vaccines targeting different indications in clinical stage studies.
The ongoing clinical activities as well as preparation for phase III study on mRNA-1273 are likely to have driven operating expenses higher in the second quarter.
We note that Pfizer PFE in collaboration with BioNTech BNTX and Sanofi SNY in collaboration with TranslateBio have also been developing mRNA-based vaccines for COVID-19.
Meanwhile, Moderna’s coronavirus development progress has attracted partnerships from other government as well global organizations namely, Coalition for Epidemic Preparedness Innovations (“CEPI”), the U.S. National Institute of Allergy and Infectious Diseases (“NIAID”) and the Biomedical Advanced Research and Development Authority ("BARDA"). These partnerships have provided grants to support the different stages of development of mRNA-1273.
The company has received a commitment of $472 million from the U.S. government's Operation Warp Speed program. This is an addition to the earlier commitment of $483 million to support late-stage development of its mRNA vaccine candidate against COVID-19 from the BARDA. These funds will be available to the company as and when needed. The Zacks Consensus Estimate for grant revenues is pegged at $21.2 million for the second quarter.
Moderna has few strategic alliances with pharma companies for the development of some of its pipeline candidates. These alliances generate collaboration revenues for the company. The Zacks Consensus Estimate for collaboration revenues is pegged at $11.7 million for the second quarter. (Read more: Moderna to Report Q2 Earnings: What's in the Cards?)
Moderna, Inc. Price and Consensus
Moderna, Inc. Price and Consensus
Moderna, Inc. Price and Consensus
Moderna, Inc. price-consensus-chart | Moderna, Inc. Quote
Zacks Rank
Moderna currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 12:52:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 12:49:56 PM
- Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors • PR Newswire (US) • 10/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 11:03:59 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/30/2024 09:45:00 AM
- Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 09/26/2024 09:45:00 AM
- Moderna, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/23/2024 09:45:00 AM
- The Gross Law Firm Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/16/2024 09:45:00 AM
- OpenAI Unveils Strawberry AI Model Series; Boeing Stock Falls 4% Amid Strike; HR Surges 20% on Growth Forecast • IH Market News • 09/13/2024 10:12:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:03:14 AM
- Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRNA • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:27 PM
- Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases • PR Newswire (US) • 09/10/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 07:29:35 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 09/09/2024 02:26:00 PM
- Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:42:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:26:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:58:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:42:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:37:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:34:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:45:44 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM